Literature DB >> 8472796

Planning of a screening programme for cervical cancer in Liguria and evaluation of the attitude of the female population towards cancer detection.

M Ferreri1, L Bonelli, A Capasso, D Barizzone, C Gustavino, P Bruzzi, L Santi.   

Abstract

In 1990 an investigation aimed at evaluating the possibility of organizing a regional screening programme for the early detection of cervical cancer was carried out in Liguria. Information on resources available for early detection of cervical cancer was obtained from 12 of 20 Public Health Units; a screening programme was feasible in 8 of them. The number of Pap tests examined was evaluated for 6 of 20 cytology laboratories. Only one laboratory examined more than 20,000 Pap tests in 1989 and, according to the international guidelines, can be a referring centre for screening. However, no information was available concerning inter- and intralaboratory quality control programmes. In the same period a population-based survey was carried out using a self-administered questionnaire in order to evaluate the attitudes of women towards cervical cancer prevention. A total of 1,454 of 4,197 women (35%) participated in the study. Younger, well educated women employed in non non-manual work were more likely to participate in the study. About 65% of the respondents had satisfactory practices with regards to the Pap test, suggesting a strong self-selection that probably resulted in a sample of women more health-conscious than the general population. In conclusion, our results suggest that major interventions should be carried out in the Public Health Units to direct resources to the needs of the population. In addition, new educational methods should be adopted to reach selected population groups to encourage them to have a Pap test performed on a regular basis.

Entities:  

Mesh:

Year:  1993        PMID: 8472796     DOI: 10.1007/bf00463084

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  8 in total

1.  Quality control in the cytology laboratory.

Authors:  M R Melamed
Journal:  Acta Cytol       Date:  1976 May-Jun       Impact factor: 2.319

2.  Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies. IARC Working Group on evaluation of cervical cancer screening programmes.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1986-09-13

3.  Twenty years' screening for cancer of the uterine cervix in Great Britain, 1964-84: further evidence for its ineffectiveness.

Authors:  M F Murphy; M J Campbell; P O Goldblatt
Journal:  J Epidemiol Community Health       Date:  1988-03       Impact factor: 3.710

4.  Cancer statistics, 1988.

Authors:  E Silverberg; J A Lubera
Journal:  CA Cancer J Clin       Date:  1988 Jan-Feb       Impact factor: 508.702

5.  Failures of the cervical cytology screening programme.

Authors:  J Chamberlain
Journal:  Br Med J (Clin Res Ed)       Date:  1984-10-06

6.  Screening for cervical cancer: a new scope for general practitioners? Results of the first year of colposcopy in general practice.

Authors:  J Chomet
Journal:  Br Med J (Clin Res Ed)       Date:  1987-05-23

7.  Survey of performance of cervical cytopathology laboratories and of screening programs in Italy. National Working Group for Quality Assurance in Cytohistopathology.

Authors:  M Branca; S Alieri; L Cialdea; P Morosini
Journal:  Tumori       Date:  1990-10-31

8.  Evaluation of screening programmes for gynaecological cancer.

Authors:  M Hakama; J Chamberlain; N E Day; A B Miller; P C Prorok
Journal:  Br J Cancer       Date:  1985-10       Impact factor: 7.640

  8 in total
  1 in total

1.  Combined effects of depressive symptoms and resting heart rate on mortality: the Whitehall II prospective cohort study.

Authors:  Hermann Nabi; Mika Kivimäki; Jean-Philippe Empana; Séverine Sabia; Annie Britton; Michael G Marmot; Martin J Shipley; Archana Singh-Manoux
Journal:  J Clin Psychiatry       Date:  2010-12-14       Impact factor: 4.384

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.